# Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

> **NCT02360319** · PHASE4 · COMPLETED · sponsor: **Vanguard Research Group** · enrollment: 489 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Any FDA approved antipsychotic agent
- **DRUG:** aripiprazole long acting injectable formulation

## Key facts

- **NCT ID:** NCT02360319
- **Lead sponsor:** Vanguard Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-11
- **Primary completion:** 2019-03-31
- **Final completion:** 2019-03-31
- **Target enrollment:** 489 (ACTUAL)
- **Last updated:** 2020-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360319, "Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02360319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*